Bio B2B 〉 Selective Search Results
Your Selection Setting ：Small Molecule；
Selective Search Results :
Biotech Companies 26 record(s)；
TSH Biopharm Co., Ltd.
Chronic disease is one of the most important issues related to life expectancy and modern civilization. It is also the niche market TSH Biopharm devotes itself to; we focus on cardiovascular and autoimmune disease, and we contribute to patients, medical institutions and society constantly by developing patentable and high-barrier specialty drugs that have a pharmacoeconomics profile
Intech Biopharm Ltd.
We are a pharmaceutical company that develops, produces and markets specialized drugs focusing on the respiratory treatment categories. By owning strong RD team and the superior HFA MDI platforms with facilities at the high level as EMA and US FDA standard, we are not only challenge high barrier generic drugs but also develop 505b2 and new combination drug for obstructive airway diseases.
Lumosa Therapeutics Co., Ltd.
Lumosa Therapeutics is dedicated to the development of innovative new drugs for the treatment of unmet medical needs in the fields of neurological and inflammatory diseases. The company is actively engaged in scientific licensing and new drug development under a “reSEARCH and DEVELOPMENT” model. We “search” for candidates with strong scientific rationale and high feasibility
INNOPHARMAX is a specialty pharmaceutical company focused in the development and commercialization of products for the treatment of oncology and specialty. We internally develop and/or acquire potential drug candidates for further clinical development as well as commercialization. We intend to use internally developed drug delivery technology platforms for improving the safety and efficacy
TaiGen Biotechnology Co., Ltd.
TaiGen Biotechnology, a public listed company in Taipei Exchange (4157.TWO), is a research-based and product-driven pharmaceutical company engaging in the development of novel therapeutics for infectious diseases, cancer and diabetes-related complications.TaiGen founded in 2001 with headquarters in Taiwan and a wholly-owned Beijing subsidiary. TaiGen's pipeline includes three
SINEW PHARMA INC.
Sinew Pharma was established in 2014 to aim at the current world urgent important unmet medical needs. The technology platform was based on the modulation of hepatic metabolic enzymes and genes. Among 6 core products, 2 were developed for the treatment of non-alcoholic steatohepatitis (NASH), 4 for the most widely used analgesics acetaminophen related hepatotoxicity.SNP-610 was approved by USFDA
CHO Pharma Inc.
CHO Pharma, founded in 2013, is a biopharmaceutical company mainly focused on the development and commercia-lization of innovative products based on the proprietary glycan engineering technologies. Together with our strategic partner, Academia Sinica in Taiwan, we strive for continuous innovation on glycan-based technology and are committ-ed to deliver best-in-class targeted and differentiated products
Oneness Biotech Co., Ltd.
We began in 2008 as a government-approved biopharmaceutical company devoted to New Drug Development. In 2011, Oneness became a listed company on the over-the-counter market in Taiwan under the approval of the Securities and Futures Bureau.Today, our vision, our mission and our strategy identify who we are as a company at Oneness.Our VisionOur goal is to become a leading international biotech
Microbio Co., Ltd.
MICROBIO, which was founded in 2000, has experienced over a decade of growth and remains dedicated to “novel therapeutics development and human lifestyle improvement”. MICROBIO Group's approach to innovative and responsible drug development has led to two successful drug approvals by the Taiwanese Food and Drug Administration (TFDA). In addition to drug development, we have expanded
Orient Pharma Co., Ltd.
Orient Pharma (OP) was established on Feb 1, 2008. It is focusing on the development and manufactureing of 505(b)(2) new drugs. There are more than 170 employee and 35% are dedicated to R&D. 70% of the employee own master or PhD degrees. Located in Yunlin county in the central of Taiwan, the Yunlin plant obtained the approval for PIC/S GMP from the Taiwan FDA
SOFIVA GENOMICS is an assembly of authoritative physicians and expert consultants in maternal-fetal medicine, cancer medicine, medical genetics, and clinical medicine. We aspire to act as both clinical physicians and research scientists and closely join fundamental medical research and clinical diagnosis together using translational medicine so as serve our mission and value in medical genetics.Our
We are a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of best-in-class novel nanomedicines that combine our proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Our extensive experience with liposome science allows us to combine speed of onset and duration of benefit and to improve API
Meet TaiRxTaiRx, Inc. was founded in 2011 under the strategic alliance of Formosa Laboratories, Inc. and Efficient Pharma Management Corp. to develop a new generation of novel NCE (CVM-1118) for cancer treatment. In 2013, TaiRx started a series of financing and expanded our product pipeline. In addition to cancer treatment, we have expanded our reach to other major diseases. Several products are under
TAHO Pharmaceuticals Ltd.
TAHO Pharmaceuticals Ltd. (TAHO) is a specialty pharmaceutical company focused on the development of pharmaceutical products based on its drug delivery technology platforms to relieve the debilitating side effects of cancer treatment and treat central nervous (CNS) system conditions. TAHO utilizes its proprietary drug delivery technologies to create products that improve the quality of life for patients
Sinphar Pharmaceutical Co., Ltd.
Upholding its philosophy, “public's health is Sinphar's ideal” Sinphar Group has accompanied the public for almost 40 years. All these time, the company has always embraced its focus on “life, health, and technology” in developing therapeutic drugs, health care foods, and medical beauty products to provide the public with the best service for protecting their health
SynCore Biotechnology Co., Ltd.
SynCore Biotechnology Co., Ltd (“SynCore”) is a biopharmaceutial company focusing on creating values of new drug by R&D and integration of technology resources. SynCore was established in 2008 and cofounded by Sinphar Group and National Health Research Institute (NHRI). SynCore inherited Sinphar's experiences which have been accumulated for more than 30 years in R&D, manufacturing
PharmaEngine, Inc. is a biopharmaceutical company established in February 2003 with funding from TTY Biopharm, National Development Fund and Taiwanese venture capital. We are a networked pharma company that operates according to a combination of "No Research Development Only (NRDO)" model and "Networked Pharma" model. Our company is led by Dr. C. Grace Yeh, and supported
Vita Genomics, Inc.
The Leading Pharmacogenomics Company in Asia PacificVita Genomics, founded in March 2001, has established its headquarters and main facility in Taipei, Taiwan since January 2002. The mission of Vita Genomics is to study and understand what affects the Asian population in order to better diagnose, treat, and eventually cure diseases. Currently, in order to provide clinical and omics services to clinical
Nang Kuang Pharmaceutical Co., Ltd.
Nang Kuang, founded in 1963, is a leading parenteral pharmaceutical company in Taiwan. The facility has passed US FDA and Japan PMDA inspections. Our major products including anticancer injections (isolator system), large volume parenterals ( LVP; PP-soft bag), aseptic parenterals (Ampoule、Vial), lyophilized injection, aseptic Pre-filled syringe、Pre-mixed IV infusion
PharmaEssentia Corporation (Taipei Exchange:6446) is a fully integrated global biopharmaceutical company delivering efficacious, safe and cost-effective therapeutic products for the treatment of human diseases while aiming to bring long lasting value to stakeholders. PharmaEssentia was founded in 2003 by a group of Taiwanese-American executives and high-ranking scientists from leading U.S. biotechnology
ScinoPharm Taiwan, Ltd.
Founded in 1997, with initial on-site operations beginning in November 1999, ScinoPharm offers a wide array of process R&D services and API manufacturing capabilities designed to satisfy customers' exact requirements and facilitate their rapid market introductions. ScinoPharm specializes in process R&D and the production of CGMP Active Pharmaceutical Ingredients (APIs).ScinoPharm targets
Foresee Pharmaceuticals Co., Ltd.
Company ProfileForesee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange. Foresee's R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery platform and derived drug products targeting specialty markets, and its transformative early stage preclinical and clinical NCE programs targeting inflammatory &
Senhwa Biosciences, Inc. (6492:TT) identifies and develops innovative therapies that have the potential to fundamentally change the way patients are treated. Developing first-in-class small molecule drugs used in cancer treatments is Senhwa's core value and corporate mission. Headquartered in Taiwan, but with a vital operational base in San Diego, California, the Senhwa Team is well positioned
GRAPE KING BIO LTD.
For 47 years, Grape King Bio has srived to be one of the top health food manufacturers in the biotechnology industry. Being an ISO22000/HACCP/NSF GMP certified manufacturer, we are able to guarantee the highest standards in product safety, quality and manufacturing. Together with our visionary and dedicated staff at Grape King Bio, we aim to take biotechnology to the next level.
Bora Pharmaceuticals Co., Ltd.
IntroductionBora Pharmaceutical is one of the premier pharmaceutical companies in Taiwan that covers the entire pharmaceutical supply chain from research and development all the way to sales and distribution. We provide pharmaceutical CDMO and CMO services for Taiwan domestic and global pharmaceutical companies around the world.Bora is USFDA, MHRA, and PIC/S certified, and we produce pharmaceuticals
GWO XI STEM CELL APPLIED TECHNOLOGY CO., LTD.
Gwo Xi Company was founded in 2004. We are developing stem cell therapies that have the potential to transform the lives of people with degeneration diseases or rare diseases. Our production platform is fully compliant with medical regulations (GTP). We have 3 clinical trials are going in Taiwan by now. In future, we will have established the PIC/S GMP grade stem cell preparation factory (15,225 m2